As GLP-1 medications become more popular, many people are searching for answers on whether they affect anxiety, depression, and broader mental health.
GLP-1 receptors are present in the brain and influence not just appetite and metabolism but also:
Neurotransmission
Neuroinflammation
Reward and mood pathways
This provides a biological basis for both potential anxiolytic effects and possible mood changes, depending on individual factors.
Mixed results from cohort and clinical research
Some cohort studies find lower incidences of anxiety and depression among long-term GLP-1 users, particularly in type 2 diabetes populations.
Large systematic analyses report conflicting results, with beneficial, neutral, and limited evidence across different studies.
Regulatory and trial data
A systematic expert reaction to mental health meta-analysis found no increased risk of anxiety or depression in clinical trials compared to placebo, and in some cases mild mood improvement.
The U.S. FDA recently requested removal of suicidal-thought warnings from GLP-1 drug labels after analyses showed no significant increase in suicidal behaviour compared to placebo.
GLP-1 medications may influence anxiety symptoms by:
Modulating neuroinflammation
Helping improve physical wellbeing and energy levels, which often impacts anxiety
Affecting neurotransmitter systems indirectly linked to mood changes
However, the evidence is not conclusive enough to consider GLP-1 medications a treatment for anxiety in clinical practice.
Most clinical trials exclude people with pre-existing psychiatric disorders, limiting how much we can generalise to those with significant anxiety.
Observational data can be confounded by weight loss itself improving mood independently of the drug's direct pharmacology.
Summary
Final Takeaways
Across women's health, addiction and anxiety:
GLP-1 medications have clear metabolic benefits and emerging non-metabolic effects.
Evidence is strongest for PCOS improvement and reduced substance use risk.
Anxiety and direct mental health impacts remain uncertain and under study.